Publications by authors named "Christophe Fruchart"

Claim this Profile
E
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.
Jean-Marie Michot, Serge Bologna, Jean-Noël Bastie, Thierry Vander Borght, Josette Brière, Christophe Fruchart

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, Emmanuel Itti, Pierre Feugier, Christophe Fruchart

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K Bouabdallah, Christophe Fruchart

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study.
Juliette Pénichoux, Hélène Lanic, Caroline Thill, Anne-Lise Ménard, Vincent Camus, Christophe Fruchart

Ann Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study.
Juliette Pénichoux, Hélène Lanic, Caroline Thill, Anne-Lise Ménard, Vincent Camus, Christophe Fruchart

Ann Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.
Asma Beldi-Ferchiou, Jean-Philippe Jais, Hervé Ghesquieres, Rene Olivier Casasnovas, Hervé Tilly, Christophe Fruchart

Br J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Vincent Camus, Aurélien Belot, Lucie Oberic, David Sibon, Hervé Ghesquières, Christophe Fruchart

Blood Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Christophe Fruchart

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Christophe Fruchart

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.
Christophe Bonnet, Jehan Dupuis, Hervé Tilly, Thierry Lamy, Christophe Fruchart

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy.
Nicolas Aide, Christophe Fruchart, Catherine Nganoa, Anne-Claire Gac, Charline Lasnon

Eur Radiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Catherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, Nicolas Mounier, Aurore Perrot, Christophe Fruchart

Br J Haematol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Laetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Christophe Fruchart

Blood· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A J Rule, Christophe Fruchart

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Franck Morschhauser, Steven Le Gouill, Pierre Feugier, Sarah Bailly, Emmanuelle Nicolas-Virelizier, Christophe Fruchart

Lancet Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Roch Houot, Guillaume Cartron, Fontanet Bijou, Sophie de Guibert, Gilles A Salles, Christophe Fruchart

Leukemia· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Emmanuel Gyan, Anne Sonet, Pauline Brice, Bruno Anglaret, Kamel Laribi, Christophe Fruchart

Br J Haematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Franck Morschhauser, Nathan H Fowler, Pierre Feugier, Reda Bouabdallah, Hervé Tilly, Christophe Fruchart

N Engl J Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
Blandine Enilorac, Charline Lasnon, Cathy Nganoa, Christophe Fruchart, Anne-Claire Gac

J Nucl Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of alteration in liver F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score.
Thibault Salomon, Catherine Nganoa, Anne-Claire Gac, Christophe Fruchart, Gandhi Damaj

Eur J Nucl Med Mol Imaging· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
Nicolas Aide, Marjolaine Talbot, Christophe Fruchart, Gandhi Damaj, Charline Lasnon

Eur J Nucl Med Mol Imaging· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
Nicolas Aide, Marjolaine Talbot, Christophe Fruchart, Gandhi Damaj, Charline Lasnon

Eur J Nucl Med Mol Imaging· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased frequencies of circulating and tumor-resident Vδ1 T cells in patients with diffuse large B-cell lymphoma.
Emilie Reboursiere, Anne-Claire Gac, Anthony Garnier, Véronique Salaun, Oumedaly Reman, Christophe Fruchart

Leuk Lymphoma· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Frédéric Peyrade, Serge Bologna, Vincent Delwail, Jean François Emile, Laurent Pascal, Christophe Fruchart

Lancet Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis